September 2016
Volume 57, Issue 12
Open Access
ARVO Annual Meeting Abstract  |   September 2016
Avastin effects on human limbal epithelial cell function and phenotype in vitro
Author Affiliations & Notes
  • Maria Notara
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Gabriele Braun
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Marie Luise Dreisow
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Felix Bock
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Claus Cursiefen
    Ophthalmology, University Hospital of Cologne, Cologne, Germany
  • Footnotes
    Commercial Relationships   Maria Notara, None; Gabriele Braun, None; Marie Dreisow, None; Felix Bock, None; Claus Cursiefen, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science September 2016, Vol.57, 4343. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Maria Notara, Gabriele Braun, Marie Luise Dreisow, Felix Bock, Claus Cursiefen; Avastin effects on human limbal epithelial cell function and phenotype in vitro. Invest. Ophthalmol. Vis. Sci. 2016;57(12):4343.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Topical application of the VEGFA inhibitor bevacizumab (Avastin) is used for antiangiogenic therapy at the cornea. While clinical studies have suggested that this off-label use of Avastin is well-tolerated with relatively few adverse effects, the impact of the drug on limbal epithelial stem cells is unknown. In this study, the effect of Avastin on the functionality and phenotype of limbal epithelial cells was investigated

Methods : The effect of different concentrations of Avastin (0 mg/ml, 0.125mg/ml, 0.5mg/ml and 1mg/ml) on human limbal epithelial cells was investigated in terms of proliferation using an alamar blue assay and migration by a scratch wound assay (SWA). Changes in phenotype were assessed using a colony forming efficiency (CFE) assay as well as immunostaining and QPCR of markers associated with basal limbal epithelial cells, differentiated corneal epithelial cells and putative stem cells including integrinβ1, cytokeratin 3 and ΔΝΡ63∝ respectively. The effect of the treatment in RNA expression of VEGFA, C and D and their receptors VEGFR1, 2 and 3 was also assessed.

Results : The different treatment groups featured no difference in proliferation and CFE as well as morphology and marker expression by immunostaining. A small but significant delay in wound healing of all the Avastin treated groups was detected at an early timepoint of 2h. QPCR assessment indicated a small but significant increase of integrinβ1 and a strong expression in cytokeratin 3 with the increasing Avastin concentrations while ΔΝΡ63∝ RNA levels remained unaffected. VEGFA RNA expression also significantly increased while VEGFC and D were unchanged. No differences were observed in the expression of VEGFR1, 2 and 3.

Conclusions : This study exhibited previously unknown short-term effects of Bevazizumab in cultured human limbal epithelial cells: Avastin-induced a dose-responsive increase of cytokeratin 3 expression, indicating a shift towards a more differentiated phenotype, as well as a delay in wound closure correlating with the delayed wound healing observed clinically with the use of Avastin. The increase in VEGFA RNA levels may reflect an autocrine defence mechanism of the limbal epithelial cells as they attempt to compensate for the neutralisation effect of Avastin. The data obtained through this in vitro approach confirm the effects of Avastin while elucidating phenotypical and functional changes in limbal epithelial cells.

This is an abstract that was submitted for the 2016 ARVO Annual Meeting, held in Seattle, Wash., May 1-5, 2016.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×